MDM2 and acute lymphoblastic leukemia: Here, we demonstrated that derepression of p53 activity through the prevention of MDM2-p53 association with the second-generation MDM2 inhibitor idasanutlin has modest p53-dependent activity against T-ALL PDX as a single agent therapy.